← All trials
NCT05373108
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 19, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- May 13, 2022
- Last posted
- May 13, 2022
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, Los AngelesLead sponsor
- American Heart AssociationCollaborator
- University of California, Los AngelesOverall official - principal investigator
- Janssen Pharmaceutica NVCollaborator
- University of California, Los AngelesOfficial
- University of California, Los AngelesSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.